Overview

Sorbinil Retinopathy Trial (SRT)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of the investigational drug sorbinil, an aldose reductase inhibitor, in preventing the development of diabetic retinopathy and neuropathy in persons with insulin-dependent diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
National Eye Institute (NEI)